Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 15, 2024 16:10 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Strengthens Leadership Team with Key Appointments
February 14, 2024 08:00 ET
|
Ocuphire Pharma
Ash Jayagopal, Ph.D., M.B.A. Appointed Chief Scientific and Development Officer Nirav Jhaveri, C.F.A, M.B.A. Appointed as Chief Financial Officer FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE...
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
February 05, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 24, 2024 16:10 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
January 04, 2024 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
November 30, 2023 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 27, 2023 16:38 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
November 27, 2023 08:00 ET
|
Ocuphire Pharma
FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing...
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
November 13, 2023 08:00 ET
|
Ocuphire Pharma
Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2...
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
November 02, 2023 08:00 ET
|
Ocuphire Pharma
Agreement on Phase 3 Primary Endpoint of 3-step Worsening on Binocular Diabetic Retinopathy Severity Scale (DRSS) Score Company Plans to Submit a Special Protocol Assessment (SPA) APX3330 has the...